Use of multidrug-resistance gene (MDR1) expression levels to predict outcome to adjuvant cisplatin/gemcitabine based chemotherapy in patients with with locally advanced urothelial cancer
Thomas Gauler, A. Hartmann, Michael Stöckle(Saarland University), Wilfried Eberhardt(National Center for Tumor Diseases), A. C. Hoffman(University of Southern California), Simone Bertz(Friedrich-Alexander-Universität Erlangen-Nürnberg), Jens Lehmann(Universität Innsbruck), Robert Stöhr(Friedrich-Alexander-Universität Erlangen-Nürnberg), Peter J. Wild(Goethe University Frankfurt), K. D. Danenberg(University of Zurich), Christina Leicht(University Hospital Regensburg)
Cited by 0
Related Papers
Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry
|Nature Methods|2014|2k
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
|The Lancet|2009|1.4k
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)
|Journal of Clinical Oncology|2017|872
Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma
|Cancer Cell|2016|660